Barclays Reaffirms Sell Rating for Genomic Health (GHDX)

Genomic Health (NASDAQ:GHDX)‘s stock had its “sell” rating reiterated by investment analysts at Barclays in a report released on Monday. They presently have a $28.00 price target on the medical research company’s stock. Barclays’ price objective would suggest a potential downside of 21.10% from the company’s previous close.

GHDX has been the topic of a number of other reports. Zacks Investment Research raised Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. JPMorgan Chase & Co. cut Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price target on the stock. in a research report on Wednesday, December 13th. ValuEngine cut Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Canaccord Genuity reissued a “buy” rating and issued a $35.00 price target on shares of Genomic Health in a research report on Wednesday, September 27th. Finally, Jefferies Group reaffirmed a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research report on Thursday, September 14th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $31.71.

Shares of Genomic Health (GHDX) traded up $0.27 on Monday, hitting $35.49. The stock had a trading volume of 207,500 shares, compared to its average volume of 209,317. Genomic Health has a 12-month low of $26.37 and a 12-month high of $37.50. The company has a market cap of $1,230.00, a PE ratio of -273.00 and a beta of 0.65.

In related news, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $31.47, for a total value of $157,350.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider James J. Vaughn sold 1,379 shares of the company’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total value of $44,831.29. The disclosure for this sale can be found here. Insiders sold a total of 60,717 shares of company stock worth $1,980,682 over the last ninety days. 46.20% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC purchased a new stake in Genomic Health during the 3rd quarter valued at $138,000. SG Americas Securities LLC raised its stake in Genomic Health by 37.8% during the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after buying an additional 1,679 shares during the last quarter. Legal & General Group Plc raised its stake in Genomic Health by 11.4% during the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after buying an additional 710 shares during the last quarter. Jane Street Group LLC purchased a new stake in Genomic Health during the 3rd quarter valued at $227,000. Finally, Parametric Portfolio Associates LLC raised its stake in Genomic Health by 5.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after buying an additional 441 shares during the last quarter. 89.67% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Barclays Reaffirms Sell Rating for Genomic Health (GHDX)” was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://transcriptdaily.com/2018/01/10/barclays-reaffirms-sell-rating-for-genomic-health-ghdx.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply